L3VLUP
ProSign in

MRK · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRKLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRK
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMRKLLY
Q3 202035 holders, $20.2bn33 holders, $14.1bn
Q4 202034 holders, $19.1bn29 holders, $17.3bn
Q1 202133 holders, $16.6bn24 holders, $23.0bn
Q2 202131 holders, $15.1bn24 holders, $27.8bn
Q3 202131 holders, $15.2bn31 holders, $29.9bn
Q4 202126 holders, $15.0bn31 holders, $34.7bn
Q1 202234 holders, $17.4bn24 holders, $35.3bn
Q2 202234 holders, $19.0bn33 holders, $42.7bn
Q3 202235 holders, $17.2bn31 holders, $43.4bn
Q4 202235 holders, $25.2bn31 holders, $46.6bn
Q1 202333 holders, $26.6bn33 holders, $44.3bn
Q2 202334 holders, $30.1bn37 holders, $59.6bn
Q3 202339 holders, $26.7bn44 holders, $67.6bn
Q4 202341 holders, $29.3bn45 holders, $73.6bn
Q1 202437 holders, $37.1bn41 holders, $95.3bn
Q2 202438 holders, $33.0bn43 holders, $110bn
Q3 202438 holders, $29.1bn45 holders, $107bn
Q4 202435 holders, $23.7bn46 holders, $93.9bn
Q1 202536 holders, $20.8bn42 holders, $98.4bn
Q2 202531 holders, $18.5bn43 holders, $93.2bn
Q3 202536 holders, $19.0bn39 holders, $86.7bn
Q4 202532 holders, $26.8bn41 holders, $123bn
Q1 202630 holders, $28.9bn39 holders, $106bn
Q2 202625 holders, $29.2bn44 holders, $132bn
MRK

Merck & Co Inc

Holders
38
Reported value
$29.1bn
Buyers
23
Sellers
17

Breadth +6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (33)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

Only MRK (5)

Eisler Capital Management Ltd, Harris Associates LP, Soros Fund Management LLC, Tudor Investment Corp, Winton Group Ltd

Only LLY (12)

Coatue Management LLC, ExodusPoint Capital Management LP, Holocene Advisors LP, Jane Street Group LLC, Marshall Wace LLP, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Viking Global Investors LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →